Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes

Trial Profile

Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Capecitabine (Primary) ; Ribociclib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms GEP14-LEECAP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 09 Dec 2016 Planned initiation date changed from 1 Apr 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top